

Cris Constantinescu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8170504/publications.pdf>

Version: 2024-02-01

220
papers

10,066
citations

36303

51
h-index

42399

92
g-index

228
all docs

228
docs citations

228
times ranked

13042
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). <i>British Journal of Pharmacology</i> , 2011, 164, 1079-1106. | 5.4 | 1,082 |
| 2 | Treatment of Neuromyelitis Optica With Rituximab. <i>Archives of Neurology</i> , 2008, 65, 1443. | 4.5 | 445 |
| 3 | Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. <i>Lancet Neurology</i> , The, 2008, 7, 796-804. | 10.2 | 438 |
| 4 | Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. <i>Brain</i> , 2009, 132, 239-249. | 7.6 | 339 |
| 5 | Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. <i>Journal of Neurology</i> , 2014, 261, 1662-1676. | 3.6 | 236 |
| 6 | Cannabinoids and the immune system: An overview. <i>Immunobiology</i> , 2010, 215, 588-597. | 1.9 | 209 |
| 7 | Fatigue in multiple sclerosis – A brief review. <i>Journal of the Neurological Sciences</i> , 2012, 323, 9-15. | 0.6 | 183 |
| 8 | Tumor Necrosis Factor α and Lymphotoxin α Are Not Required for Induction of Acute Experimental Autoimmune Encephalomyelitis. <i>Journal of Experimental Medicine</i> , 1997, 185, 2177-2182. | 8.5 | 182 |
| 9 | A prospective study of conditions associated with multiple sclerosis in a cohort of 658 consecutive outpatients attending a multiple sclerosis clinic. <i>Multiple Sclerosis Journal</i> , 2004, 10, 575-581. | 3.0 | 182 |
| 10 | Mutations in FRMD7, a newly identified member of the FERM family, cause X-linked idiopathic congenital nystagmus. <i>Nature Genetics</i> , 2006, 38, 1242-1244. | 21.4 | 180 |
| 11 | Validation of the Multiple Sclerosis International Quality of Life questionnaire. <i>Multiple Sclerosis Journal</i> , 2008, 14, 219-230. | 3.0 | 159 |
| 12 | Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 1349-1359. | 3.0 | 159 |
| 13 | TLR2 Stimulation Drives Human Naive and Effector Regulatory T Cells into a Th17-Like Phenotype with Reduced Suppressive Function. <i>Journal of Immunology</i> , 2011, 187, 2278-2290. | 0.8 | 152 |
| 14 | Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells. <i>Nature Communications</i> , 2014, 5, 5056. | 12.8 | 137 |
| 15 | Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. <i>Immunology Letters</i> , 1998, 62, 25-31. | 2.5 | 134 |
| 16 | Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. <i>Brain</i> , 2013, 136, 2298-2304. | 7.6 | 127 |
| 17 | Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon β -1a (Rebif) treatment trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2003, 74, 1090-1094. | 1.9 | 122 |
| 18 | Astrocytes as antigen-presenting cells: expression of IL-12/IL-23. <i>Journal of Neurochemistry</i> , 2005, 95, 331-340. | 3.9 | 119 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Cannabinoid receptor agonists are mitochondrial inhibitors: A unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. <i>Biochemical and Biophysical Research Communications</i> , 2007, 364, 131-137. | 2.1 | 119 |
| 20 | Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis. <i>Journal of Immunology</i> , 1998, 161, 5097-104. | 0.8 | 109 |
| 21 | fMRI analysis of active, passive and electrically stimulated ankle dorsiflexion. <i>NeuroImage</i> , 2009, 44, 469-479. | 4.2 | 106 |
| 22 | Effects of pro-inflammatory cytokines on cannabinoid CB_1 and CB_2 receptors in immune cells. <i>Acta Physiologica</i> , 2015, 214, 63-74. | 3.8 | 95 |
| 23 | Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 324-331. | 1.9 | 95 |
| 24 | Plasma endocannabinoid levels in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2009, 287, 212-215. | 0.6 | 94 |
| 25 | Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation. <i>Scientific Reports</i> , 2017, 7, 14542. | 3.3 | 93 |
| 26 | Use of combined conventional and quantitative MRI to quantify pathology related to cognitive impairment in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 437-441. | 1.9 | 88 |
| 27 | Glucocorticoids increase $CD4^{+}CD25^{high}$ cell percentage and Foxp3 expression in patients with multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2009, 119, 239-245. | 2.1 | 87 |
| 28 | “Importance sampling” in MS: Use of diffusion tensor tractography to quantify pathology related to specific impairment. <i>Journal of the Neurological Sciences</i> , 2005, 237, 13-19. | 0.6 | 86 |
| 29 | Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31. | 1.4 | 86 |
| 30 | Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2015, 2, e117. | 6.0 | 86 |
| 31 | Increased iron accumulation occurs in the earliest stages of demyelinating disease: an ultra-high field susceptibility mapping study in Clinically Isolated Syndrome. <i>Multiple Sclerosis Journal</i> , 2013, 19, 896-903. | 3.0 | 83 |
| 32 | Cutting Edge: C3, a Key Component of Complement Activation, Is Not Required for the Development of Myelin Oligodendrocyte Glycoprotein Peptide-Induced Experimental Autoimmune Encephalomyelitis in Mice. <i>Journal of Immunology</i> , 2001, 166, 723-726. | 0.8 | 82 |
| 33 | Deep gray matter and fatigue in MS. <i>Journal of Neurology</i> , 2006, 253, 896-902. | 3.6 | 78 |
| 34 | The association between human endogenous retroviruses and multiple sclerosis: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0172415. | 2.5 | 77 |
| 35 | Intracolonic Vancomycin for Pseudomembranous Colitis. <i>New England Journal of Medicine</i> , 1993, 329, 583-583. | 27.0 | 72 |
| 36 | Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. <i>Lancet Neurology</i> , The, 2010, 9, 672-680. | 10.2 | 70 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. <i>Acta Neurologica Scandinavica</i> , 2003, 108, 401-406. | 2.1 | 66 |
| 38 | Curcumin modulation of IFN α 2 and IL α 12 signalling and cytokine induction in human T cells. <i>Journal of Cellular and Molecular Medicine</i> , 2007, 11, 1129-1137. | 3.6 | 65 |
| 39 | TLR2 Stimulation Regulates the Balance between Regulatory T Cell and Th17 Function: A Novel Mechanism of Reduced Regulatory T Cell Function in Multiple Sclerosis. <i>Journal of Immunology</i> , 2015, 194, 5761-5774. | 0.8 | 65 |
| 40 | Measurement of Spinal Cord Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2004, 14, 20S. | 2.0 | 63 |
| 41 | Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1250-1257. | 3.0 | 62 |
| 42 | Stroop performance in multiple sclerosis: Information processing, selective attention, or executive functioning?. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 805-814. | 1.8 | 61 |
| 43 | Effects of the Angiotensin Converting Enzyme Inhibitor Captopril on Experimental Autoimmune Encephalomyelitis. <i>Immunopharmacology and Immunotoxicology</i> , 1995, 17, 471-491. | 2.4 | 59 |
| 44 | Interaction between cytokines, cannabinoids and the nervous system. <i>Immunobiology</i> , 2010, 215, 606-610. | 1.9 | 59 |
| 45 | Measurement of cervical spinal cord cross-sectional area by MRI using edge detection and partial volume correction. <i>Journal of Magnetic Resonance Imaging</i> , 2005, 21, 197-203. | 3.4 | 58 |
| 46 | Concurrence of multiple sclerosis and amyotrophic lateral sclerosis in patients with hexanucleotide repeat expansions of <i>C9ORF72</i> . <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 79-87. | 1.9 | 57 |
| 47 | Brain tractography using Q-ball imaging and graph theory: Improved connectivities through fibre crossings via a model-based approach. <i>NeuroImage</i> , 2010, 49, 2444-2456. | 4.2 | 56 |
| 48 | Development of a simple and sensitive HPLC-UV method for the simultaneous determination of cannabidiol and δ^9 -tetrahydrocannabinol in rat plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 145-151. | 2.8 | 56 |
| 49 | Magnetic resonance imaging of the cervical spinal cord in multiple sclerosis. <i>Journal of Neurology</i> , 2003, 250, 307-315. | 3.6 | 54 |
| 50 | <i>Helicobacter pylori</i> infection reduces disease severity in an experimental model of multiple sclerosis. <i>Frontiers in Microbiology</i> , 2015, 6, 52. | 3.5 | 54 |
| 51 | Delirium as a presenting feature in COVID-19: Neuroinvasive infection or autoimmune encephalopathy?. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 68-70. | 4.1 | 54 |
| 52 | Luzindole, a Melatonin Receptor Antagonist, Suppresses Experimental Autoimmune Encephalomyelitis. <i>Pathobiology</i> , 1997, 65, 190-194. | 3.8 | 53 |
| 53 | Serum Angiotensin-Converting Enzyme in Multiple Sclerosis. <i>Archives of Neurology</i> , 1997, 54, 1012-1015. | 4.5 | 52 |
| 54 | The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. <i>European Journal of Immunology</i> , 1998, 28, 2227-2233. | 2.9 | 51 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?. <i>Journal of Neurochemistry</i> , 2010, 115, 829-844. | 3.9 | 51 |
| 56 | Th17/Th1 phenotype in demyelinating disease. <i>Cytokine</i> , 2010, 50, 19-23. | 3.2 | 51 |
| 57 | Increased Osteopontin Levels in the Cerebrospinal Fluid of Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 2008, 65, 633-5. | 4.5 | 50 |
| 58 | Astrocytes and Microglia Produce Interleukin-12 p40. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 328-333. | 3.8 | 47 |
| 59 | Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. <i>American Journal of Translational Research (discontinued)</i> , 2016, 8, 3448-59. | 0.0 | 47 |
| 60 | Measurement of Spinal Cord Atrophy in Multiple Sclerosis. , 2004, 14, 20-26. | | 46 |
| 61 | Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. <i>Therapeutic Advances in Neurological Disorders</i> , 2011, 4, 3-14. | 3.5 | 45 |
| 62 | Modulation of Susceptibility and Resistance to an Autoimmune Model of Multiple Sclerosis in Prototypically Susceptible and Resistant Strains by Neutralization of Interleukin-12 and Interleukin-4, Respectively. <i>Clinical Immunology</i> , 2001, 98, 23-30. | 3.2 | 44 |
| 63 | Current and future disease-modifying therapies in multiple sclerosis. <i>International Journal of Clinical Practice</i> , 2010, 64, 637-650. | 1.7 | 44 |
| 64 | Pathogenesis of neuroimmunologic diseases. <i>Immunologic Research</i> , 1998, 17, 217-227. | 2.9 | 43 |
| 65 | Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Autoimmune Diseases. <i>Inflammation and Allergy: Drug Targets</i> , 2009, 8, 182-190. | 1.8 | 43 |
| 66 | Spinal Cord Imaging in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2005, 15, 94S-102S. | 2.0 | 41 |
| 67 | Tobacco smoking and excess mortality in multiple sclerosis: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1091-1095. | 1.9 | 41 |
| 68 | Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2019, 329, 24-34. | 2.3 | 41 |
| 69 | Functionally Relevant White Matter Degradation in Multiple Sclerosis: A Tract-based Spatial Meta-Analysis. <i>Radiology</i> , 2015, 275, 89-96. | 7.3 | 39 |
| 70 | Hookworm Treatment for Relapsing Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1089. | 9.0 | 39 |
| 71 | The Role of Osteopontin in Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS). <i>Inflammation and Allergy: Drug Targets</i> , 2010, 9, 249-256. | 1.8 | 38 |
| 72 | A comparison of phase imaging and quantitative susceptibility mapping in the imaging of multiple sclerosis lesions at ultrahigh field. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2016, 29, 543-557. | 2.0 | 38 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Upper cervical spinal cord cross-sectional area in relapsing remitting multiple sclerosis: Application of a new technique for measuring cross-sectional area on magnetic resonance images. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 26, 61-65. | 3.4 | 37 |
| 74 | Expression of Activity-Dependent Neuroprotective Protein in the Immune System: Possible Functions and Relevance to Multiple Sclerosis. <i>NeuroImmunoModulation</i> , 2010, 17, 120-125. | 1.8 | 37 |
| 75 | Increase in the iron content of the substantia nigra and red nucleus in multiple sclerosis and clinically isolated syndrome: A 7 Tesla MRI study. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1065-1070. | 3.4 | 37 |
| 76 | Spotlight on teriflunomide. <i>International MS Journal</i> , 2008, 15, 62-8. | 0.3 | 36 |
| 77 | Serum uric acid levels in optic neuritis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 278-280. | 3.0 | 35 |
| 78 | Hypothalamic involvement assessed by T1 relaxation time in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1442-1449. | 3.0 | 35 |
| 79 | Association of a deficit of arousal with fatigue in multiple sclerosis: Effect of modafinil. <i>Neuropharmacology</i> , 2013, 64, 380-388. | 4.1 | 35 |
| 80 | Olfactory disturbances as the initial or most prominent symptom of multiple sclerosis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 1011-1012. | 1.9 | 34 |
| 81 | Murine macrophages stimulated with central and peripheral nervous system myelin or purified myelin proteins release inflammatory products. <i>Neuroscience Letters</i> , 2000, 287, 171-174. | 2.1 | 34 |
| 82 | Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000, 6, 378-381. | 3.0 | 34 |
| 83 | Cannabinoids and experimental models of multiple sclerosis. <i>Immunobiology</i> , 2010, 215, 647-657. | 1.9 | 33 |
| 84 | Siponimod for the treatment of secondary progressive multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 143-150. | 1.8 | 33 |
| 85 | Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12. <i>Journal of Neuroimmunology</i> , 2000, 107, 1-7. | 2.3 | 32 |
| 86 | Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study. <i>Nicotine and Tobacco Research</i> , 2018, 20, 589-595. | 2.6 | 32 |
| 87 | A regularized two-tensor model fit to low angular resolution diffusion images using basis directions. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 199-209. | 3.4 | 31 |
| 88 | Modulation of Regulatory T Cells in Health and Disease: Role of Toll-Like Receptors. <i>Inflammation and Allergy: Drug Targets</i> , 2009, 8, 124-129. | 1.8 | 30 |
| 89 | Orexin A (hypocretin-1) levels are not reduced while cocaine/amphetamine regulated transcript levels are increased in the cerebrospinal fluid of patients with multiple sclerosis: No correlation with fatigue and sleepiness. <i>Journal of the Neurological Sciences</i> , 2011, 307, 127-131. | 0.6 | 29 |
| 90 | The essential role of t cells in multiple sclerosis: A reappraisal. <i>Biomedical Journal</i> , 2014, 37, 34. | 3.1 | 29 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 1995, 130, 178-182. | 0.6 | 28 |
| 92 | Subjective discomfort in children receiving 3T MRI and experienced adults' perspective on children's tolerability of 7T: a cross-sectional questionnaire survey. <i>BMJ Open</i> , 2014, 4, e006094. | 1.9 | 28 |
| 93 | Reciprocal Regulation of Substance P and IL-12/IL-23 and the Associated Cytokines, IFN γ /IL-17: A Perspective on the Relevance of This Interaction to Multiple Sclerosis. <i>Journal of NeuroImmune Pharmacology</i> , 2015, 10, 457-467. | 4.1 | 28 |
| 94 | INTERLEUKIN 15 STIMULATES PRODUCTION OF MATRIX METALLOPROTEINASE-9 AND TISSUE INHIBITOR OF METALLOPROTEINASE-1 BY HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS. <i>Cytokine</i> , 2001, 13, 244-247. | 3.2 | 27 |
| 95 | Effects of glucocorticoids on STAT4 activation in human T cells are stimulus-dependent. <i>Journal of Leukocyte Biology</i> , 2006, 80, 133-144. | 3.3 | 27 |
| 96 | Discrepant Effects of Human Interferon-gamma on Clinical and Immunological Disease Parameters in a Novel Marmoset Model for Multiple Sclerosis. <i>Journal of NeuroImmune Pharmacology</i> , 2012, 7, 253-265. | 4.1 | 27 |
| 97 | Combined pharmacologic and surgical approach to acquired nystagmus due to multiple sclerosis. <i>American Journal of Ophthalmology</i> , 2002, 134, 780-782. | 3.3 | 26 |
| 98 | Comorbidity in multiple sclerosis: its temporal relationships with disease onset and dose effect on mortality. <i>European Journal of Neurology</i> , 2020, 27, 105-112. | 3.3 | 26 |
| 99 | Melanin, melatonin, melanocyte-stimulating hormone, and the susceptibility to autoimmune demyelination: A rationale for light therapy in multiple sclerosis. <i>Medical Hypotheses</i> , 1995, 45, 455-458. | 1.5 | 25 |
| 100 | IL-12 reverses the suppressive effect of the CD40 ligand blockade on experimental autoimmune encephalomyelitis (EAE). <i>Journal of the Neurological Sciences</i> , 1999, 171, 60-64. | 0.6 | 25 |
| 101 | Central inflammation versus peripheral regulation in multiple sclerosis. <i>Journal of Neurology</i> , 2011, 258, 1518-1527. | 3.6 | 25 |
| 102 | Advances in the treatment of relapsing - Remitting multiple sclerosis. <i>Biomedical Journal</i> , 2014, 37, 41. | 3.1 | 25 |
| 103 | Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension. <i>American Journal of Clinical and Experimental Immunology</i> , 2013, 2, 234-44. | 0.2 | 24 |
| 104 | Coordinate based random effect size meta-analysis of neuroimaging studies. <i>NeuroImage</i> , 2017, 153, 293-306. | 4.2 | 23 |
| 105 | Graph Theoretic Analysis of Brain Connectomics in Multiple Sclerosis: Reliability and Relationship with Cognition. <i>Brain Connectivity</i> , 2020, 10, 95-104. | 1.7 | 23 |
| 106 | Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1517-1531. | 3.1 | 22 |
| 107 | MOG-IgG-associated demyelination: focus on atypical features, brain histopathology and concomitant autoimmunity. <i>Journal of Neurology</i> , 2020, 267, 359-368. | 3.6 | 22 |
| 108 | Recent developments in interferon-based therapies for multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 665-680. | 3.1 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Extra-Hippocampal Subcortical Limbic Involvement Predicts Episodic Recall Performance in Multiple Sclerosis. PLoS ONE, 2012, 7, e44942. | 2.5 | 21 |
| 110 | Coordinate Based Meta-Analysis of Functional Neuroimaging Data Using Activation Likelihood Estimation; Full Width Half Max and Group Comparisons. PLoS ONE, 2014, 9, e106735. | 2.5 | 20 |
| 111 | Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis. Neurology and Therapy, 2019, 8, 45-57. | 3.2 | 20 |
| 112 | Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). Current Eye Research, 2000, 20, 71-76. | 1.5 | 19 |
| 113 | Effect of DAB389IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats. Journal of the Neurological Sciences, 2007, 263, 59-69. | 0.6 | 19 |
| 114 | Cost-Effectiveness of Disease-Modifying Therapies in Multiple Sclerosis. Current Neurology and Neuroscience Reports, 2012, 12, 592-600. | 4.2 | 19 |
| 115 | Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 162, 43-49. | 4.3 | 19 |
| 116 | Quality of life in multiple sclerosis is dominated by fatigue, disability and self-efficacy. Journal of the Neurological Sciences, 2021, 426, 117437. | 0.6 | 19 |
| 117 | Suppression of experimental autoimmune neuritis by phosphodiesterase inhibitor pentoxifylline. Journal of the Neurological Sciences, 1996, 143, 14-18. | 0.6 | 18 |
| 118 | Coordinate Based Meta-Analysis of Functional Neuroimaging Data; False Discovery Control and Diagnostics. PLoS ONE, 2013, 8, e70143. | 2.5 | 18 |
| 119 | Investigating Brain Microstructural Alterations in Type 1 and Type 2 Diabetes Using Diffusion Tensor Imaging: A Systematic Review. Brain Sciences, 2021, 11, 140. | 2.3 | 18 |
| 120 | Lymphocyte-specific inducible expression of potassium channel beta subunits. Journal of Neuroimmunology, 1997, 77, 8-16. | 2.3 | 17 |
| 121 | SUNCT in Multiple Sclerosis. Cephalalgia, 2006, 26, 891-893. | 3.9 | 17 |
| 122 | Autoimmune associations in multiple sclerosis. Nature Reviews Neurology, 2010, 6, 591-592. | 10.1 | 17 |
| 123 | Time- and Region-Specific Season of Birth Effects in Multiple Sclerosis in the United Kingdom. JAMA Neurology, 2016, 73, 954. | 9.0 | 17 |
| 124 | Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. Journal of NeuroVirology, 2017, 23, 839-844. | 2.1 | 17 |
| 125 | Experimental infection with the hookworm, <i>Necator americanus</i> , is associated with stable gut microbial diversity in human volunteers with relapsing multiple sclerosis. BMC Biology, 2021, 19, 74. | 3.8 | 17 |
| 126 | IL-12 inhibits glucocorticoid-induced T cell apoptosis by inducing GMEB1 and activating PI3K/Akt pathway. Immunobiology, 2012, 217, 118-123. | 1.9 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Epilepsy and associated mortality in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2019, 26, 342. | 3.3 | 16 |
| 128 | A different response to cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection in UK people with multiple sclerosis (PwMS) compared to controls. <i>Journal of Infection</i> , 2020, 80, 320-325. | 3.3 | 16 |
| 129 | The impact of smoking cessation on multiple sclerosis disease progression. <i>Brain</i> , 2022, 145, 1368-1378. | 7.6 | 16 |
| 130 | Skeletal muscle myosin is the autoantigen for experimental autoimmune myositis. <i>Experimental and Molecular Pathology</i> , 2003, 74, 238-243. | 2.1 | 15 |
| 131 | Corpus callosum changes following shunting for hydrocephalus: case report and review of the literature. <i>Clinical Neurology and Neurosurgery</i> , 2005, 107, 351-354. | 1.4 | 15 |
| 132 | Helminth Therapy for MS. <i>Current Topics in Behavioral Neurosciences</i> , 2014, 26, 195-220. | 1.7 | 15 |
| 133 | Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices. <i>Current Neurology and Neuroscience Reports</i> , 2016, 16, 68. | 4.2 | 15 |
| 134 | What role does tobacco smoking play in multiple sclerosis disability and mortality? A review of the evidence. <i>Neurodegenerative Disease Management</i> , 2015, 5, 19-25. | 2.2 | 14 |
| 135 | Investigating Microstructural Changes in White Matter in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Neurite Orientation Dispersion and Density Imaging. <i>Brain Sciences</i> , 2021, 11, 1151. | 2.3 | 14 |
| 136 | Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-182. | 2.8 | 14 |
| 137 | Migraine and Raynaud Phenomenon: Possible Late Complications of Kawasaki Disease. <i>Headache</i> , 2002, 42, 227-229. | 3.9 | 13 |
| 138 | The endocannabinoid system: a revolving plate in neuro-immune interaction in health and disease. <i>Amino Acids</i> , 2013, 45, 95-112. | 2.7 | 13 |
| 139 | Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 621-630. | 3.3 | 13 |
| 140 | Cognitive Rehabilitation for Attention and Memory in people with Multiple Sclerosis: study protocol for a randomised controlled trial (CRAMMS). <i>Trials</i> , 2015, 16, 556. | 1.6 | 13 |
| 141 | Coordinate based meta-analysis does not show grey matter atrophy in narcolepsy. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 57, 297-298. | 6.1 | 13 |
| 142 | Reduced Myelin Signal in Normal-appearing White Matter in Neuromyelitis Optica Measured by 7T Magnetic Resonance Imaging. <i>Scientific Reports</i> , 2019, 9, 14378. | 3.3 | 13 |
| 143 | Intrathecal gadolinium-enhanced magnetic resonance myelography in the detection of CSF leak. <i>Neurology</i> , 2006, 67, 1522-1522. | 1.1 | 12 |
| 144 | A presenilin 1 mutation (Arg278Ser) associated with early onset Alzheimer's disease and spastic paraparesis. <i>Journal of the Neurological Sciences</i> , 2007, 260, 78-82. | 0.6 | 12 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Multiple Sclerosis, Lymphoma and Nasopharyngeal Carcinoma: The Central Role of Epstein-Barr Virus?. <i>European Neurology</i> , 2010, 63, 29-35. | 1.4 | 12 |
| 146 | Role of oral teriflunomide in the management of multiple sclerosis. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 539. | 2.2 | 12 |
| 147 | Urinary Free Kappa Light Chain Levels in Chronic Progressive Multiple Sclerosis. <i>Pathobiology</i> , 1994, 62, 29-33. | 3.8 | 11 |
| 148 | A comparative audit of anticardiolipin antibodies in oligoclonal band negative and positive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 378-380. | 3.0 | 11 |
| 149 | Ehlersâ€”Danlos syndrome and multiple sclerosis: a possible association. <i>Multiple Sclerosis Journal</i> , 2008, 14, 567-570. | 3.0 | 11 |
| 150 | Prognostic factors for long-term outcomes in relapsingâ€”remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2016, 2, 205521731666640. | 1.0 | 11 |
| 151 | Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success. <i>Multiple Sclerosis Journal</i> , 2020, 26, 266-271. | 3.0 | 11 |
| 152 | Iron Rims as an Imaging Biomarker in MS: A Systematic Mapping Review. <i>Diagnostics</i> , 2020, 10, 968. | 2.6 | 11 |
| 153 | Diagnostic modalities in multiple sclerosis: Perspectives in children. <i>Biomedical Journal</i> , 2014, 37, 50. | 3.1 | 11 |
| 154 | Smoking Attributable Risk in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2022, 13, 840158. | 4.8 | 11 |
| 155 | Atopic Optic Neuritis. <i>Ocular Immunology and Inflammation</i> , 2006, 14, 125-127. | 1.8 | 10 |
| 156 | Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study. <i>BMJ Open</i> , 2015, 5, e007806-e007806. | 1.9 | 10 |
| 157 | PEGylated IFN β -1a in the treatment of multiple sclerosis. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1077-1084. | 3.1 | 10 |
| 158 | Sevenâ€”Tesla Magnetization Transfer Imaging to Detect Multiple Sclerosis White Matter Lesions. <i>Journal of Neuroimaging</i> , 2018, 28, 183-190. | 2.0 | 10 |
| 159 | Cognitive rehabilitation for attention and memory in people with multiple sclerosis: a randomized controlled trial (CRAMMS). <i>Clinical Rehabilitation</i> , 2020, 34, 229-241. | 2.2 | 10 |
| 160 | Dorsolateral prefrontal circuit effective connectivity mediates the relationship between white matter structure and PASAT â€” performance in multiple sclerosis. <i>Human Brain Mapping</i> , 2021, 42, 495-509. | 3.6 | 10 |
| 161 | Eye Movement Involvement in Parry-Romberg Syndrome: A Clinicopathologic Case Report. <i>Strabismus</i> , 2008, 16, 119-121. | 0.7 | 9 |
| 162 | Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1219-1228. | 3.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Beta interferons as immunotherapy in multiple sclerosis: a new outlook on a classic drug during the COVID-19 pandemic. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 691-697. | 0.5 | 9 |
| 164 | Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle. <i>Pharmaceutics</i> , 2021, 13, 1349. | 4.5 | 9 |
| 165 | Histogram analysis of quantitative T_1 and MT maps from ultrahigh field MRI in clinically isolated syndrome and relapsing-remitting multiple sclerosis. <i>NMR in Biomedicine</i> , 2015, 28, 1374-1382. | 2.8 | 8 |
| 166 | Congenital monocular elevation deficiency associated with a novel <i>TUBB3</i> gene variant. <i>British Journal of Ophthalmology</i> , 2020, 104, 547-550. | 3.9 | 8 |
| 167 | PAF-R on activated T cells: Role in the IL-23/Th17 pathway and relevance to multiple sclerosis. <i>Immunobiology</i> , 2021, 226, 152023. | 1.9 | 8 |
| 168 | Reciprocal effects of IFN- γ and IL-12 on STAT4 activation and cytokine induction in T cells. <i>Journal of Leukocyte Biology</i> , 2007, 81, 1562-1567. | 3.3 | 7 |
| 169 | Parasite immunomodulation in autoimmune disease: focus on multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2009, 5, 487-489. | 3.0 | 7 |
| 170 | MRI-Based Measurement of Brain Stem Cross-Sectional Area in Relapsing-Remitting Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2015, 25, 1002-1006. | 2.0 | 7 |
| 171 | The future of multiple sclerosis treatments. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1341-1356. | 2.8 | 7 |
| 172 | Laquinimod (ABR-215062) for the treatment of relapsing multiple sclerosis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 49-57. | 3.1 | 7 |
| 173 | Localised Grey Matter Atrophy in Multiple Sclerosis and Clinically Isolated Syndrome—A Coordinate-Based Meta-Analysis, Meta-Analysis of Networks, and Meta-Regression of Voxel-Based Morphometry Studies. <i>Brain Sciences</i> , 2020, 10, 798. | 2.3 | 7 |
| 174 | Vegetable oils composition affects the intestinal lymphatic transport and systemic bioavailability of co-administered lipophilic drug cannabidiol. <i>International Journal of Pharmaceutics</i> , 2022, 624, 121947. | 5.2 | 7 |
| 175 | Long term azathioprine fails to prevent onset of multiple sclerosis: report of two cases. <i>Multiple Sclerosis Journal</i> , 2000, 6, 362-363. | 3.0 | 6 |
| 176 | A drug discovery case history of Δ^9 -tetrahydrocannabinol, cannabidiol™. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 437-452. | 5.0 | 6 |
| 177 | Coordinate based meta-analysis does not show grey matter atrophy in narcolepsy. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 102, 427-429. | 6.1 | 6 |
| 178 | Coordinate based meta-analysis of networks in neuroimaging studies. <i>NeuroImage</i> , 2020, 205, 116259. | 4.2 | 6 |
| 179 | Increased IL-2 and Reduced TGF- β Upon T-Cell Stimulation are Associated with GM-CSF Upregulation in Multiple Immune Cell Types in Multiple Sclerosis. <i>Biomedicines</i> , 2020, 8, 226. | 3.2 | 6 |
| 180 | Neurological Disorders Associated With COVID-19 Hospital Admissions: Experience of a Single Tertiary Healthcare Center. <i>Frontiers in Neurology</i> , 2021, 12, 640017. | 2.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | Multiple sclerosis findings in the spinal cord. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1203-1211. | 2.8 | 5 |
| 182 | Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. <i>Journal of the Neurological Sciences</i> , 2021, 431, 120039. | 0.6 | 5 |
| 183 | Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110576. | 3.5 | 5 |
| 184 | Clinical and subclinical neurological involvement in children of conjugal multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 1995, 1, 170-172. | 3.0 | 4 |
| 185 | Cytokines in Idiopathic Intracranial Hypertension CSF. <i>Headache</i> , 2010, 50, 323-325. | 3.9 | 4 |
| 186 | Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders. <i>Current Pharmaceutical Design</i> , 2011, 17, 3191-3201. | 1.9 | 4 |
| 187 | Reduced EDSS progression in multiple sclerosis patients treated with modafinil for three years or more compared to matched untreated subjects. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 131-135. | 2.0 | 4 |
| 188 | Gastrointestinal influences in multiple sclerosis: Focus on the role of the microbiome. <i>Clinical and Experimental Neuroimmunology</i> , 2018, 9, 2-12. | 1.0 | 4 |
| 189 | Pet Ownership and Multiple Sclerosis during COVID-19. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12683. | 2.6 | 4 |
| 190 | Easy to interpret coordinate based meta-analysis of neuroimaging studies: Analysis of brain coordinates (ABC). <i>Journal of Neuroscience Methods</i> , 2022, 372, 109556. | 2.5 | 4 |
| 191 | Environmental Influences in Experimental Autoimmune Encephalomyelitis. , 2005, , 523-546. | | 3 |
| 192 | Symptomatic Uveitis and Multiple Sclerosis. <i>Neuro-Ophthalmology</i> , 2008, 32, 49-54. | 1.0 | 3 |
| 193 | DAB389IL-2 suppresses autoimmune inflammation in the CNS and inhibits T cell-mediated lysis of glial target cells. <i>Experimental and Molecular Pathology</i> , 2014, 96, 108-117. | 2.1 | 3 |
| 194 | Intestinal Bacterial Antigens, Toxin-Induced Pathogenesis and Immune Cross-Reactivity in Neuromyelitis Optica and Multiple Sclerosis. , 2016, , 227-236. | | 3 |
| 195 | Decreased interferon- γ induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 233-238. | 2.1 | 3 |
| 196 | Neuro-Behçet's Disease " Clinical Features, Diagnosis and Differential Diagnosis. <i>European Neurological Review</i> , 2018, 13, 93. | 0.5 | 3 |
| 197 | Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS). <i>Current Eye Research</i> , 2000, 20, 71-6. | 1.5 | 3 |
| 198 | The four self-efficacy trajectories among people with multiple sclerosis: Clinical associations and implications. <i>Journal of the Neurological Sciences</i> , 2022, 436, 120188. | 0.6 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Possible Role of Corticosteroids in Nervous System Plasticity: Improvement in Amblyopia After Optic Neuritis in the Fellow Eye Treated with Steroids. <i>Neurorehabilitation and Neural Repair</i> , 2001, 15, 223-227. | 2.9 | 2 |
| 200 | Adjuvants in EAE. , 2005, , 73-84. | | 2 |
| 201 | Special Issue 8, 2010 introduction. <i>Immunobiology</i> , 2010, 215, 587. | 1.9 | 2 |
| 202 | <i>Helicobacter pylori</i> , Experimental Autoimmune Encephalomyelitis, and Multiple Sclerosis. , 2016, , 97-122. | | 2 |
| 203 | DAB₃₈₉IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice. <i>Immunopharmacology and Immunotoxicology</i> , 2017, 39, 318-329. | 2.4 | 2 |
| 204 | Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited. <i>European Journal of Neurology</i> , 2018, 25, 905-906. | 3.3 | 2 |
| 205 | Hypothermia in Multiple Sclerosis: Beyond the Hypothalamus? A Case Report and Review of the Literature. <i>Case Reports in Neurological Medicine</i> , 2018, 2018, 1-16. | 0.4 | 2 |
| 206 | An Absence of Epsteinâ€Barr Virus Reactivation and Associations with Disease Activity in People with Multiple Sclerosis Undergoing Therapeutic Hookworm Vaccination. <i>Vaccines</i> , 2020, 8, 487. | 4.4 | 2 |
| 207 | B Cells and Antibodies in Experimental Autoimmune Encephalomyelitis. , 2005, , 269-281. | | 1 |
| 208 | Maintenance Intravenous Immunoglobulin Treatment for Multiple Sclerosis Coexisting with Ehlers-Danlos Syndrome and Muir-Torre Syndrome: A Case Study. <i>Neurology and Therapy</i> , 2020, 9, 605-610. | 3.2 | 1 |
| 209 | Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2000, 6, 378-381. | 3.0 | 1 |
| 210 | Effects of substance P on human cerebral microvascular endothelial cell line hCMEC/D3 are mediated exclusively through a truncated NK-1 receptor and depend on cell confluence. <i>Neuropeptides</i> , 2022, 95, 102265. | 2.2 | 1 |
| 211 | Absence of electromyographically detectable acute neuromuscular transmission defects after intramuscular interferon- β administration. <i>Journal of Neurology</i> , 1998, 245, 333-334. | 3.6 | 0 |
| 212 | The Neuron and Axon in Experimental Autoimmune Encephalomyelitis. , 2005, , 133-149. | | 0 |
| 213 | Hormonal and Gender Influences on Experimental Autoimmune Encephalomyelitis. , 2005, , 547-560. | | 0 |
| 214 | Cytokines in Experimental Autoimmune Encephalomyelitis. , 2005, , 283-311. | | 0 |
| 215 | Title is missing!. <i>Journal of the Neurological Sciences</i> , 2008, 271, 214-215. | 0.6 | 0 |
| 216 | Letter to the Editor: A case of dysphagia with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2008, 14, 716-717. | 3.0 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|----|-----------|
| 217 | Neurological Complications of Anti-TNF Treatments and Other Neurological Aspects of Inflammatory Bowel Disease. , 2016, , 211-225. | | 0 |
| 218 | Beta Interferon. , 2009, , 1-4. | | 0 |
| 219 | The Effects of Cannabinoids on Immune Cells, Responses and Diseases. , 2012, , 307-359. | | 0 |
| 220 | Association of Multiple sclerosis with Other Autoimmune Diseases. , 2013, , 341-356. | | 0 |